AAV vector vs. Lentiviral vectors for gene therapy

Scroll Down

Viral vectors are effective and efficient tools for gene therapy, transducing and delivering genes to target cell populations and achieving sustainable expression. The efficacy of a gene therapy is heavily dependent on the delivery vehicle chosen.

The most popular vectors for gene therapy are derived from adeno-associated viral vectors (AAV vectors) and lentiviral vectors. Both vectors can induce gene expression and cause limited immune response in the host.

AAV and lentiviral vector platforms offer their own unique pros and cons that could influence the viability and success of the gene therapy program chosen. With extensive expertise, Genezen understands the importance of making the right viral vector choice.

For insight into which viral vector could be best suited for your next gene therapy project, download our AAV vs. LV vector comparative overview by completing the form to the right.

You may also be interested in...

Genezen Enters Licensing Agreement with CSL…

February 21, 2024 – Genezen, a leading cell and gene therapy...

Read more

Bringing Therapies to Life with Multi-Vector…

Rapid expansion in biotechnology platforms and advancement in genetic editing technologies...

Read more

LVV Approaches to Pseudotyping and Plasmid…

As cell and gene therapies continue to provide unprecedented advancements in...

Read more

Genezen Announces the Appointment of Steven…

BOSTON, MA and FISHERS, IN. – March 13, 2023 – Genezen,...

Read more